MYGN
Myriad Genetics Inc
4.50$
+11.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 30.0% | 31.3% | 31.9% | 30.4% | 29.8% | 28.3% | 31.5% | 28.8% | 30.1% | 30.0% | 31.3% | 33.4% | 31.2% | |
| 70.0% | 68.7% | 68.1% | 69.6% | 70.2% | 71.7% | 68.5% | 71.2% | 69.9% | 70.0% | 68.7% | 66.6% | 68.8% | |
| 12.5% | 10.7% | 12.3% | 12.8% | 13.4% | 15.3% | 14.0% | 12.0% | 13.7% | 12.2% | 13.5% | 13.1% | 13.1% | |
| 70.9% | 16.6% | 35.2% | 34.1% | 32.4% | 70.3% | 33.9% | 31.3% | 33.0% | 26.5% | 31.0% | 30.3% | 30.2% | |
| 101.3% | 84.6% | 81.8% | 86.8% | 79.6% | 90.2% | 83.3% | 225.7% | 81.2% | 72.7% | 84.0% | 87.0% | 81.1% | |
| -31.3% | -16.0% | -13.8% | -17.3% | -9.4% | -18.5% | -14.8% | -154.5% | -11.3% | -2.7% | -15.3% | -20.4% | -12.2% | |
| 0.5% | 0.5% | 0.2% | 0.4% | 0.4% | 0.3% | 0.4% | 0.7% | 1.8% | 2.1% | 2.0% | 2.1% | 2.0% | |
| -31.9% | -16.4% | -12.8% | -17.6% | -9.9% | -18.6% | -15.0% | -155.1% | -12.7% | -4.2% | -17.0% | -22.3% | -13.9% | |
| 0.1% | -0.6% | 0.0% | -0.2% | 0.4% | 1.6% | -15.0% | 0.0% | 0.6% | -0.5% | – | 0.3% | – | |
| -31.9% | -15.9% | -12.9% | -17.4% | -10.4% | -20.2% | -0.1% | -155.1% | -13.3% | -3.8% | -17.0% | -22.7% | -14.0% | |
| -24.0% | -8.3% | -4.8% | -10.1% | -2.3% | -11.2% | -7.2% | -147.8% | -4.8% | 3.9% | -8.7% | -13.6% | -5.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.